Biogen Inc. (BIIB, Financial) has recently received a reaffirmation of its stock rating and price target by the analyst Laura Chico from Wedbush. On June 12, 2025, it was announced that the biotech company would retain a 'Neutral' rating.
The price target set by Wedbush remains unchanged at $121.00 USD. This consistent outlook suggests no anticipated fluctuations according to the latest analysis by the brokerage firm. Historically, the price target has also remained stable at $121.00 USD.
These findings are significant for investors following Biogen's (BIIB, Financial) market performance, particularly those assessing its long-term investment potential. As the financial landscape evolves, stakeholders continue to monitor the company's strategic decisions and market dynamics.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $169.94 with a high estimate of $260.00 and a low estimate of $115.00. The average target implies an upside of 27.88% from the current price of $132.89. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.27, suggesting a upside of 58.98% from the current price of $132.89. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
